Comparison of treatment modalities between r-axSpA and nr-axSpA: pooled analysis
| Variable | N studies | r-axSpA | nr-axSpA | Rr (95% CI) | P value | I2 | ||
| N patients | Pooled percentage (95% CI) | N patients | Pooled percentage (95% CI) | |||||
| NSAIDs | 13 | 3365 | 73.5% (63.1 to 81.8) | 1727 | 69.1% (55.5 to 80.0) | 1.04 (0.96 to 1.12) | 0.379 | 79.8% |
| csDMARDs | 12 | 3179 | 29.6% (20.5 to 39.9) | 1355 | 28.5% (21.9 to 36.2) | 1.04 (0.83 to 1.29) | 0.726 | 75.5% |
| bDMARDs | 9 | 3834 | 28.7% (19.7 to 39.7) | 1318 | 26.2% (16.1 to 39.6) | 1.08 (0.89 to 1.32) | 0.444 | 71.0% |
| Systemic glucocorticoids | 8 | 2769 | 8.5% (5.2 to 13.4) | 903 | 10.1% (8.2 to 12.3) | 0.93 (0.73 to 1.18) | 0.547 | 38.6% |
1/13 studies for NSAIDs outcome are from RCTs; 1/12 studies for csDMARDs outcome are from RCTs; 1/9 studies for bDMARDs outcome are from RCTs; 0/8 studies for Systemic glucocorticoids are from RCTs.
bDMARD, biological disease-modifying antirheumatic drug; csDMARD, synthetic disease-modifying antirheumatic drug; nr-axSpA, non-radiographic axial Spondyloarthritis; NSAIDs, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial Spondyloarthritis; RR, relative risk.